论文部分内容阅读
目的:探讨ADAM10在胰腺癌患者外周血中的表达及其临床意义。方法:应用酶联免疫吸附试验法(ELISA)检测40例胰腺癌患者和20例健康体检者的外周血ADAM10的表达水平,分析其与临床病理特征的关系。结果:胰腺癌患者血清ADAM10水平显著高于正常对照组(P<0.01);胰腺癌患者血清中ADAM10的表达水平与胰腺癌淋巴结转移、远处转移及TNM分期密切相关(P<0.05),且行根治性手术切除的胰腺癌患者ADAM10表达水平低于姑息性手术切除的患者(P<0.05);ADAM10对胰腺癌诊断的敏感度、特异性分别为51.7%、76.9%,联合检测CA19-9有助于提高胰腺癌诊断敏感度,但特异性有所下降;根治性切除后胰腺癌患者血清中ADAM10水平明显下降。结论:胰腺癌癌患者血清中ADAM10水平明显增高,检测血清ADAM10有助于胰腺癌的诊断和治疗。
Objective: To investigate the expression of ADAM10 in peripheral blood of patients with pancreatic cancer and its clinical significance. Methods: The expression of ADAM10 in peripheral blood of 40 patients with pancreatic cancer and 20 healthy controls was detected by enzyme-linked immunosorbent assay (ELISA), and its relationship with clinicopathological features was analyzed. Results: Serum ADAM10 levels in patients with pancreatic cancer were significantly higher than those in normal controls (P <0.01). ADAM10 expression in pancreatic cancer patients was closely related to lymph node metastasis, distant metastasis and TNM stage of pancreatic cancer (P <0.05) The expression of ADAM10 in patients with radical resection of pancreatic cancer was significantly lower than that in patients undergoing palliative resection (P <0.05). The sensitivity and specificity of ADAM10 in the diagnosis of pancreatic cancer were 51.7% and 76.9% respectively. The combined detection of CA19-9 Help to improve the diagnostic sensitivity of pancreatic cancer, but the specificity decreased; radical prostatectomy in patients with serum ADAM10 levels were significantly decreased. Conclusion: The level of ADAM10 in the serum of patients with pancreatic cancer is significantly higher. Detecting serum ADAM10 is helpful for the diagnosis and treatment of pancreatic cancer.